Merck announced that its cancer drug Keytruda has been approved to treat a type of head and neck cancer by the U.S. Food and Drug Administration.
According to Merck, Keytruda can now be used as a monotherapy and in combination with a common chemotherapy regimen, to treat previously untreated patients with head and neck squamous cell carcinoma.
The approval is based on a late-stage trial in which Keytruda showed a significant improvement in overall survival in cancer patients.
Keytruda was first approved for advanced melanoma in 2014.
Read the Reuters report.
Don't miss your Daily Dose. Sign up to get news like this delivered right to your inbox.